An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra) in Subjects With Primary Immunodeficiency
Phase of Trial: Phase IV
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Acronyms HiLo
- Sponsors CSL Behring
- 25 Feb 2019 Results assessing the tolerability of higher infusion parameters of IgPro20 using forced upward titration design (n=45), presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 31 Dec 2018 Status changed from active, no longer recruiting to completed.
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.